^
    Back
    Association details:
    Biomarker:FANCA mutation
    Cancer:Prostate Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Urol
    Title:

    When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials

    Published date:
    08/17/2020
    Excerpt:
    Emerging data suggest that the greatest efficacy with single-agent PARP inhibitors is seen in mCRPC patients with germline or somatic BRCA1/2 alterations (especially BRCA2 or biallelic mutations), with potential efficacy also observed in men with PALB2 and FANCA mutations.
    DOI:
    10.1016/j.euo.2020.07.005